News

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks
Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...
Business Wire1d
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...
Fierce Biotech1d
Arrowhead says beleaguered Sarepta has 60 days to pay $100M in milestone
Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...
Sarepta Owes $100 Million to Partner as Financial Pressure Grows
Arrowhead Pharmaceuticals Inc. said Monday that it’s owed a $100 million milestone payment from Sarepta Therapeutics Inc. within the next two months, pressuring the beleaguered biotech company just ...
Arrowhead Pharmaceuticals Earns $100M Milestone Payment From Sarepta Therapeutics
Arrowhead Pharmaceuticals said it earned a $100 million milestone payment from Sarepta Therapeutics. The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets ...
Fierce Biotech13d
Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...